Last reviewed · How we verify

Prolastin-C — Competitive Intelligence Brief

Prolastin-C (Prolastin-C) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 protease inhibitor (augmentation therapy). Area: Pulmonology / Respiratory.

marketed Alpha-1 protease inhibitor (augmentation therapy) Alpha-1 antitrypsin (AAT); serine protease inhibitor Pulmonology / Respiratory Biologic Live · refreshed every 30 min

Target snapshot

Prolastin-C (Prolastin-C) — Grifols Therapeutics LLC. Prolastin-C is a purified human alpha-1 protease inhibitor (AAT) that replaces deficient or dysfunctional alpha-1 antitrypsin to protect lung tissue from enzymatic degradation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prolastin-C TARGET Prolastin-C Grifols Therapeutics LLC marketed Alpha-1 protease inhibitor (augmentation therapy) Alpha-1 antitrypsin (AAT); serine protease inhibitor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 protease inhibitor (augmentation therapy) class)

  1. Grifols Therapeutics LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prolastin-C — Competitive Intelligence Brief. https://druglandscape.com/ci/prolastin-c. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: